EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The immunogenic potential of AZD1402 (Elarekibep) T-cell epitopes in healthy volunteers and drug-exposed clinical trial participants

Liam Farrell, Stephanie M Bates, Alexander Walker, Monday Ogese, Xiaoli Meng, Sian Piper, John Mo, Katy Saide, Jorrit Hornberg, David Close, Ian Wallace, Catherine J Betts und 1 weitere

Archives of Toxicology · 2026-08 · 100 (8) · 3535-3552

DOI: 10.1007/s00204-026-04403-1 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Archives of Toxicology, online erschienen am 28.04.2026. Verfasst von Liam Farrell und 12 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Drug Safety Science, Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK. liam.farrell@liverpool.ac.uk. Hauptthemen laut MEDLINE: Epitopes, T-Lymphocyte. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

AZD1402 (Elarekibep) is a novel anticalin with engineered IL-4Rα antagonist binding properties that was under development for inhaled treatment of asthma. Structural similarity to tear-lipocalin is thought to limit immunogenicity risk; however, a range of treatment-emergent hypersensitivity-like adverse events were observed in a clinical study. This study aimed to (i) explore the activation of drug-exposed human T-cells with AZD1402- and tear lipocalin-derived peptides, (ii) characterise any T-cell epitopes contained within AZD1402 and (iii) define the nature of any response. Peripheral blood mononuclear cells (PBMC) from AZD1402-exposed study participants, alongside AZD1402-naïve donors, were cultured with AZD1402 and AZD1402-derived overlapping 18mer peptides. Proliferation and cytokine secretion were measured. T-cell clones were generated to characterise the diversity of T-cell epitopes and reactivity against equivalent tear-lipocalin peptides. AZD1402 contained multiple epitopes located in engineered “hotspot” regions of the molecule that activated PBMC and MHC class II-restricted CD4 + T-cell clones from both study participants and AZD1402-naïve donors. T-cell stimulatory peptides contained amino acid substitutions generated through mutagenesis to create AZD1402 target binding properties; similar T-cell epitopes were not found in tear-lipocalin. Detection of T-cell clones responsive towards AZD1402 and AZD1402-derived peptides provides evidence that immunogenic epitopes are formed naturally through processing of the AZD1402. These data describe a recall immunogenicity risk associated with AZD1402 and provide a framework by which to explore the immunogenic potential of modified sequences within anticalin or other large molecule therapeutics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Epitopes, T-LymphocyteHumansMaleAdultFemaleLeukocytes, MononuclearHealthy VolunteersCytokinesT-LymphocytesLymphocyte ActivationLipocalinsCell ProliferationYoung Adult

Stichwörter der Autor:innen

AnticalinHumanHypersensitivityImmune-mediated adverse eventT-cells

Substanzen

Epitopes, T-LymphocyteCytokinesLipocalins

Autor:innen und Institutionen

  • Centre for Drug Safety Science, Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK. liam.farrell@liverpool.ac.uk.
  • Safety Sciences, Clinical Pharmacology & Safety Sciences, AstraZeneca R&D, Cambridge, UK.
  • Centre for Drug Safety Science, Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK.
  • Respiratory and Immunology, AstraZeneca R&D, Cambridge, UK.
  • Chief Medical Office, Research & Development, Patient Safety Biopharma AstraZeneca, Gothenburg, Sweden.
  • Safety Sciences, Clinical Pharmacology & Safety Sciences, AstraZeneca R&D, Gothenburg, Sweden.

Förderung

  • Medical Research Council

Zitieren

APA

Farrell, L., Bates, S. M., Walker, A., Ogese, M., Meng, X., Piper, S., Mo, J., Saide, K., Hornberg, J., Close, D., Wallace, I., Betts, C. J., & Naisbitt, D. J. (2026). The immunogenic potential of AZD1402 (Elarekibep) T-cell epitopes in healthy volunteers and drug-exposed clinical trial participants. Archives of Toxicology, 100(8), 3535-3552. https://doi.org/10.1007/s00204-026-04403-1

Vancouver

Farrell L, Bates SM, Walker A, Ogese M, Meng X, Piper S, et al. The immunogenic potential of AZD1402 (Elarekibep) T-cell epitopes in healthy volunteers and drug-exposed clinical trial participants. Archives of Toxicology. 2026;100(8):3535-3552. doi:10.1007/s00204-026-04403-1

BibTeX
@article{Farrell2026,
  author = {Farrell, Liam and Bates, Stephanie M and Walker, Alexander and Ogese, Monday and Meng, Xiaoli and Piper, Sian and Mo, John and Saide, Katy and Hornberg, Jorrit and Close, David and Wallace, Ian and Betts, Catherine J and Naisbitt, Dean J},
  title = {The immunogenic potential of AZD1402 (Elarekibep) T-cell epitopes in healthy volunteers and drug-exposed clinical trial participants},
  journal = {Archives of Toxicology},
  year = {2026},
  volume = {100},
  number = {8},
  pages = {3535--3552},
  doi = {10.1007/s00204-026-04403-1}
}
Kostenlos starten →